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Background: Convincing evidence is lacking on the benefit of follow-up biopsy in celiac
disease. Regardless, achieving mucosal recovery (MR) has remained a desirable goal
of therapy. We aimed to conduct a systematic review to determine whether MR is a
protective factor and persisting villous atrophy (PVA) has negative consequences on
long-term outcomes of celiac disease.
Methods: Seven databases were searched for articles discussing celiac patients
subjected to a gluten-free diet who had a follow-up biopsy, and clinical and laboratory
characteristics were reported by follow-up histology (MR vs. PVA). Outcomes included
clinical symptoms, mortality, malignant tumors, nutritional parameters, and metabolic
bone disease. Comparative and descriptive studies were included. Since data proved
to be ineligible for meta-analysis, the evidence was synthesized in a systematic review.
Results: Altogether, 31 studies were eligible for systematic review. Persisting symptoms
were more frequently associated with PVA than with MR, although a lot of symptom-free
patients had PVA and a lot of symptomatic patients achieved MR. PVA might be a risk
factor of lymphomas, but mortality and the overall rate of malignant tumors seemed
independent of follow-up histology. Patients with PVA tended to develop metabolic
bone disease more often, although fracture risk remained similar in the groups except
in hip fractures of which PVA was a risk factor. Reports on nutritional markers are
only anecdotal.
Conclusions: The limited evidence calls for high-quality prospective cohort studies to
be arranged to clarify the exact role of follow-up histology in celiac disease.
Keywords: celiac disease, mucosal recovery, persistent villous atrophy, follow-up biopsies, gluten-free diet
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INTRODUCTION
Celiac disease (CeD) is a systemic disorder with an increasing
worldwide prevalence of ∼1% (Di Sabatino and Corazza, 2009;
Catassi et al., 2014). In CeD, the immune-mediated destruction of
small intestinal villous architecture is triggered by dietary gluten
(Reilly et al., 2017).
Rationale of the Study
Although the value of intestinal biopsy at diagnosis is beyond
dispute (Bai et al., 2013; Rubio-Tapia et al., 2013; Ludvigsson
et al., 2014), the role of follow-up biopsy is a matter of
controversy (Pekki et al., 2017). While the restitution of
intestinal villi is expected on a strict gluten-free diet, the mucosa
fails to restore entirely in a considerable fraction of patients
(Szakacs et al., 2017). Recent guidelines recommend a follow-
up biopsy if signs and symptoms persist or relapse despite
strict adherence to a gluten-free diet (Bai et al., 2013; Rubio-
Tapia et al., 2013; Ludvigsson et al., 2014). However, reports
proposed that neither the resolution of symptoms (Bardella
et al., 2007; Biagi et al., 2014; Fang et al., 2017; Mahadev
et al., 2017) nor a strict dietary adherence (Szakacs et al.,
2017) guarantees mucosal recovery (MR). One might expect that
CeD patients with persistent villous atrophy (PVA) experience a
less favorable disease course than those achieving MR (Haines
et al., 2008), although convincing evidence is lacking. Yet,
achieving MR has remained a desirable goal in CeD. The
importance of the topic roots in the burden imposed by the
endoscopic procedures and duodenal histological sampling as
well as in the subsequent clinical decisions made upon follow-
up histology.
Objective of the Study
With this systematic review, we aimed to be the
first who systematically collect all available evidence
on the impact of follow-up histology (MR vs.
PVA) on disease characteristics and clinical course
of CeD.
Research Question
Are CeD patients who have not achieved MR exposed to adverse
clinical outcomes more frequently than those patients who have
achieved MR?
METHODS
Study Design
This systematic review was reported in accordance with the
Preferred Reporting Items for Systematic reviews and Meta-
Analyses 2009 (Moher et al., 2009).
Abbreviations: SF-36, 36-Item Short Form Health Survey; CeD, celiac disease;
GSRS, Gastrointestinal Symptom Rating Scale; HR, hazard ratio; IBS, irritable
bowel syndrome; MR, mucosal recovery; NS, non-significant; OR, odds ratio;
PGWB, Psychological General Well-Being Index; PVA, persistent villous atrophy.
Participants and Exposure
Participants of this systematic review include CeD patients
subjected to a gluten-free diet. The exposure of interest is the
follow-up duodenal histology assessed as either MR or PVA.
Systematic Review Protocol
The study protocol was registered a priori on PROSPERO
under CRD42017069815.
Search Strategy
We performed a systematic literature search in MEDLINE
(via PubMed), Embase, Cochrane Controlled Register of
Trials (CENTRAL), Web of Science, Scopus, WHO Global
Index Medicus, and ClinicalTrials.gov from inception up
to 14th September 2019 for relevant articles. Free-text
terms and Medical Subject Headings were combined into
a query, as follows: celiac AND (“mucosal recovery” OR
“mucosal healing” OR “mucosal atrophy” OR “intestinal
atrophy” OR “duodenal atrophy” OR “villous atrophy” OR
“persistent mucosal damage” OR “follow-up biopsy” OR “follow-
up duodenal biopsy” OR “follow-up intestinal biopsy” OR
“follow-up small intestinal biopsy” OR “follow-up histology”
OR “repeated biopsy” OR “repeated histology” OR “control
biopsy” OR “control histology”). No filters were imposed upon
the search.
Relevant cited articles were explored by reviewing the
reference lists of included papers. Citing articles were identified
with Google Scholar.
Data Sources, Study Selection, and Data
Extraction
Eligibility Criteria
Eligible papers discussed CeD patients subjected to a gluten-free
diet with an available record of duodenal follow-up histology,
and reported on disease and patients characteristics by follow-
up histology. Analytical and descriptive full-text articles or
conference abstracts but not case studies were included without
language restriction to reduce publication bias.
In our previous meta-analysis, we experienced a substantial
variance in the definition of MR across studies (Szakacs et al.,
2017). In this systematic review, we defined MR as the resolution
of villous atrophy at follow-up biopsy assessed as “non-atrophic”
histology based on crypt height:villous depth ratio, Marsh grades
0-2, Marsh-Oberhuber grades 0-2, or Corazza-Villanacci grade
A; while PVA was defined as “atrophic” histology, Marsh grade
3, Marsh-Oberhuber grade 3, or Corazza-Villanacci grade B1-
B2 (Marsh, 1992; Oberhuber et al., 1999; Corazza and Villanacci,
2005).
Disease and patients characteristics included signs and
symptoms, vitamin and mineral levels, anemia, body mass index,
metabolic bone disease, malignant tumors and other co-morbid
conditions, and long-term mortality.
Selection and Data Collection
Records were combined in a reference manager software
(EndNote X7.4, Clarivate Analytics, Philadelphia, PA, the USA)
to remove duplicates and overlapping database content. Then,
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the standard three-step selection was performed by title, abstract
and full-texts. Each step was carried out by two investigators in
duplicate. Discrepancies were resolved by third-party arbitration.
K-statistics was used to measure the agreement between the
investigators after each step.
Numeric and text data were extracted by two investigators
onto a pre-defined Excel sheet, discrepancies were resolved by
consensus. Although we contacted the authors of original studies
for further raw data via email, we discarded these data from the
systematic review when we realized that the material is ineligible
for meta-analysis due to several reasons (as detailed later).
Design of the Studies Included and Quality
Assessment
First, the design of the included papers was identified. Then,
quality indicators were chosen based on the Quality in Prognostic
Studies tool (Hayden et al., 2006), as follows:
• way of recruitment,
• diagnosis of CeD (only biopsy-verified cases or not),
• the recency of diagnosis (newly diagnosed patients or treated
patients were included),
• representativeness of study population to the general CeD
population (based on the inclusion and exclusion criteria of
the individual studies),
• timing of follow-up biopsy (taken prospectively after
enrolment or earlier),
• time elapsed between the diagnosis of CeD and the follow-
up biopsy, and that between the follow-up biopsy and the
measurement of outcomes,
• definition of PVA (histological classification),
• biopsy sampling site,
• timing of outcome assessment (prospectively after enrolment
or earlier),
• definitions of outcomes (with cut-off values if applicable),
• blinding,
• adherence to a gluten-free diet (strict or not), and
• statistical considerations (the analysis directly compared the
clinical characteristics by MR and PVA or not and the analysis
was adjusted for reasonable confounding factors or not).
FIGURE 1 | Flowchart of the search and selection process.
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TABLE 1 | Characteristics of the studies included.
Study Setting Study population and design Definition of
villous atrophy
and sampling
site
Recruitment Age Biopsy-
proven
CeD?
Representative
population?a
Newly
diagnosed
CeD?
Prospectively
taken follow-up
biopsy?
Bardella et al. (2007) Italy (single-center) Consecutive pts Adults
and
children
Yes No No No Marsh-Oberhuber
3a−c, duodenum
Cammarota et al.
(2007)
Italy (2-center) Consecutive pts Adults Yes Yes No Yes Marsh-Oberhuber
3a−c, duodenum
Carroccio et al. (2008) Italy (single-center) Consecutive
symptomatic pts
and randomly
selected matched
asymptomatic pts
Adults Yes Yes No Yes Marsh-Oberhuber
3a−c, duodenum
Ciacci et al. (2002) Italy (single-center) Consecutive pts Adults Yes Yes No No Marsh 3, small
intestine
Cornell et al. (2016) Poland
(single-center)
Consecutive
volunteer
Adults Yes Yes No Yes Marsh 3,
duodenum
Dickey et al. (2008) Northern Ireland
(single-center)
Consecutive pts Adults Yes Yes No Yes Marsh 3,
duodenum
Fang et al. (2017) The USA
(Single-center)
Consecutive pts Adults (?) No No No Corazza-Villanacci
B1−2, duodenum
Ghazzawi et al. (2014) The USA
(single-center)
Consecutive pts Children Yes Yes No No Marsh 3, small
intestine
Haere et al. (2016) Norway
(single-center)
Consecutive pts
by invitation
Adults Yes Yes No Yes Marsh-Oberhuber
3a−c, duodenum
Kaukinen et al. (2007) Finland
(single-center)
Consecutive pts
with persistent
villous atrophy and
randomly selected
pts with mucosal
recovery
Adults (?) Yes No No Vh/Cr<2,
duodenum,
jejunum
Kemppainen et al.
(1998)
Finland
(single-center)
Post-hoc analysis
of a randomized
trial
Adults Yes Yes No No Not reported
(“atrophic”),
duodenum
Koskinen et al. (2010) Finland
(single-center)
Consecutive pts Adults
and
children
Yes No Yes/Nob Yes Vh/Cr<2, jejunum
Lebwohl et al.
(2013a,b); Lebwohl
et al. (2014, 2015a,b),
Emilsson et al. (2018),
Ludvigsson et al.
(2018), Kurien et al.
(2018)
Sweden
(28-center)
Consecutive pts
(nationwide
sample)
Adults
and
children
Yes Yes No No Marsh 3, small
intestine
Leonard et al. (2017) Italy (2-center) Consecutive pts Children Yes Yes No No Marsh-Oberhuber
3a−c, duodenum
Mahadev et al. (2017) North-America,
Ireland, UK,
Norway, and
Finland
(multicenter)
Post-hoc analysis
of a randomized
trial
Adults (?) No No No Vh/Cr ≤2,
duodenum
Pekki et al. (2015) Finland
(single-center)
Consecutive pts Adults Yes Yes (?) Yes Vh/Cr<2,
duodenum
Pekki et al. (2017) Finland
(single-center)
Consecutive
volunteers
Adults Yes Yes No No Vh/Cr (“atrophic”),
small intestine
Rubio-Tapia et al.
(2010)
The USA
(single-center)
Consecutive pts Adults Yes Yes No No Vh/Cr<3,
duodenum
(Continued)
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TABLE 1 | Continued
Study Setting Study population and design Definition of
villous atrophy
and sampling
site
Recruitment Age Biopsy-
proven
CeD?
Representative
population?a
Newly
diagnosed
CeD?
Prospectively
taken follow-up
biopsy?
Selby et al. (1999) Australia
(single-center)
Symptomatic and
asymptomatic pts
from a previous
food-intolerance
study
Adults Yes Yes No No Vh/Cr<2,
duodenum
Souroujon et al. (1982) Israel
(single-center)
Consecutive pts Adults
and
Children
Yes Yes Yes Yes Not reported
(“atrophic”), small
intestine
Thornquist et al. (1993) Norway
(single-center)
Consecutive pts
by invitation
Adults Yes Yes No Yes/Noc Alexander III-IV,
jejunum
Tuire et al. (2012) Finland
(single-center)
Consecutive
volunteers
Adults Yes Yes No Yes Marsh 3,
duodenum
Valdimarsson et al.
(1994)
Sweden
(single-center)
Consecutive pts
with persistent
villous atrophy and
matched pts with
mucosal recovery
Adults (?) Yes No No Alexander III-IV,
small intestine
Walters et al. (1995) UK (single center) Consecutive pts
by invitation
Adults Yes No No Yes/Noc Not reported
(“atrophic”), small
intestine
aStudy population is considered representative to the average CeD population if the study avoided inappropriate exclusions.
bThe study observed a group of newly diagnosed CeD patients for the short-term and a group of followed-up patients for the long-term.
cNot all patients were newly diagnosed.
(?) indicates uncertainty. CeD, celiac disease; pts, patients; Vh/Cr, villous height/crypt depth ratio.
RESULTS
Study Selection and Characteristics
After careful search and selection (Figure 1), 31 papers were
included in the systematic review (Souroujon et al., 1982;
Thornquist et al., 1993; Valdimarsson et al., 1994; Walters
et al., 1995; Kemppainen et al., 1998; Selby et al., 1999; Ciacci
et al., 2002; Bardella et al., 2007; Cammarota et al., 2007;
Kaukinen et al., 2007; Carroccio et al., 2008; Dickey et al.,
2008; Koskinen et al., 2010; Rubio-Tapia et al., 2010; Tuire
et al., 2012; Lebwohl et al., 2013a,b, 2014, 2015a,b; Ghazzawi
et al., 2014; Pekki et al., 2015, 2017; Cornell et al., 2016;
Haere et al., 2016; Fang et al., 2017; Leonard et al., 2017;
Mahadev et al., 2017; Emilsson et al., 2018; Kurien et al., 2018;
Ludvigsson et al., 2018) (Table 1). Cohen’s κ representing inter-
reviewer agreement was 0.72 (substantial), 0.79 (substantial),
and 0.92 (almost perfect) for selection by title, abstract, and
full-text; respectively.
Out of the 31 papers, eight retrieved data on different
outcomes from the Swedish CeD registry; therefore, study
populations partially overlap (Lebwohl et al., 2013a,b, 2014,
2015a,b; Emilsson et al., 2018; Kurien et al., 2018; Ludvigsson
et al., 2018).
Highlights of the Last Five Years
In this subchapter, we summarize the findings of the studies
which investigated the prognostic role of follow-up histology
and were published after January 2015 (Lebwohl et al., 2013a,
2015a; Pekki et al., 2015, 2017; Haere et al., 2016; Fang et al.,
2017; Mahadev et al., 2017; Emilsson et al., 2018; Kurien et al.,
2018; Ludvigsson et al., 2018). Eight studies were conducted
in Scandinavia, one in the USA, and there was another
multicenter study from Europe and North-America. Evidence
from univariate analysis suggested a borderline association of
PVA with persisting symptoms (OR = 1.656 with CI: 0.949–
2.889; p = 0.076 favoring mucosal recovery) (Fang et al., 2017),
which was not confirmed by co-variate-adjusted analysis of the
baseline cohort of patients of a multicenter randomized trial on
symptomatic CeD patients (Mahadev et al., 2017). Conclusions
from three Scandinavian studies on symptom and well-being
scores corroborated these findings (Pekki et al., 2015, 2017;
Haere et al., 2016). PVA might be associated with lower lumbar
T-score measured at 1 year after diagnosis, although neither
the risk of osteoporosis at 5 years after diagnosis nor that of
fractures at 2 years after diagnosis was higher in this group
(Pekki et al., 2015, 2017). Decreased vitamin D and calcium
levels might contribute to the impaired bone mineral density
(Fang et al., 2017). Regarding other nutrients and minerals,
zinc deficiency should be highlighted (39 vs. 14% in patients
with PVA and MR, respectively; p = 0.0005). The effect of
PVA did not manifest itself regarding erythropoiesis: three
studies reported similar hemoglobin levels and rate of anemia
in patients with PVA and MR (Pekki et al., 2015; Fang et al.,
2017; Mahadev et al., 2017). Rate of malignant tumors and
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TABLE 2 | Persistent villous atrophy in studies including only symptomatic or asymptomatic celiac patients.
Study Symptoms assessed
prospectively?
Symptoms assessed
at the time of
follow-up biopsy?
Only strict
GFD?
Symptoms N0 of pts with persistent
villous atrophy/total
(% of total)
Timing of follow-up
biopsy
(from CeD diagnosis)
ASYMPTOMATIC POPULATION
Bardella et al. (2007) No Yes Yes Not specified 71 cases/114 pts
(62)
2 years (median) with 1–23
years (range)
Walters et al. (1995) (?) (?) Yes Not specified 9 cases/17 pts
(53)
2 years (min)
Koskinen et al. (2010) Yes Yes (?) Specifieda 21 cases/71 pts (30) 1 years
Yes Yes (?) 2 cases/105 pts
(2)
8 years (median) with 2–41
years (range)
Cornell et al. (2016) Yes Yes (?) Not specified 9 cases/20 pts
(45)
4 m-36 years (range)
SYMPTOMATIC POPULATION
Mahadev et al. (2017) No Yes Yes Specifiedb 511 cases/1,345 pts
(38)
4 years (median) with 1
years (min)
aSymptoms included abdominal complaints, malabsorption, and extraintestinal symptoms.
bSymptoms include bloating, tiredness, abdominal pain, diarrhea, nausea, constipation, heartburn, and headache. (?) indicates uncertainty. CeD, celiac disease; GFD, gluten-free diet;
m, month; min, minimum; pts, patients.
that of lymphomas were not significantly different in histology
groups in two studies 5 and 8 years after diagnosis (Pekki et al.,
2015, 2017). Similar neutral associations were found on the
rate of cardiovascular diseases (Lebwohl et al., 2015a; Mahadev
et al., 2017), serious infections including sepsis, streptococcal,
pneumococcal, influenza, herpes zoster, and Clostridium difficile
infections (Emilsson et al., 2018), and adverse pregnancy
outcomes (Lebwohl et al., 2015b). MR seemed to be a protective
factor against respiratory and dermatological diseases (Pekki
et al., 2017). In contrast, anxiety and depression co-occurred
more frequently withMR (Ludvigsson et al., 2018) as did epilepsy
(Kurien et al., 2018). With respect to overall mortality, a higher
rate was reported with PVA on 8-years follow-up (14 vs. 9%) but
the difference was not statistically significant (p= 0.259).
Narrative Review
In this subchapter, we summarize all available evidence published
on the effect of MR and PVA on the outcomes of CeD.
Symptoms, Symptom Scores and Quality of Life
In asymptomatic patients, PVA rates ranged from 2 to 62%
(Walters et al., 1995; Bardella et al., 2007; Koskinen et al., 2010;
Cornell et al., 2016). In symptomatic patients, PVA rate was 38%
(Mahadev et al., 2017) (Table 2). Six studies reported symptoms
as dichotomies (symptomatic vs. asymptomatic) (Thornquist
et al., 1993; Selby et al., 1999; Kaukinen et al., 2007; Carroccio
et al., 2008; Fang et al., 2017; Leonard et al., 2017). In univariate
analysis, the percentage points of symptomatic patients with
PVA and MR were 55 vs. 70% (p = NS) (Leonard et al.,
2017), 69 vs. 57% (p = 0.076) (Fang et al., 2017), and 80
vs. 25% (p < 0.0001) (Carroccio et al., 2008), respectively
(Table 3). Only one study adjusted for reasonable co-variates
where the adjusted OR was 3.2, 95% CI: 1.6–6.4 (p = 0.001),
indicating that patients with PVA tended to be symptomatic
more often (Carroccio et al., 2008). Regarding the individual
symptoms, only one study adjusted for co-variates where none
of the symptoms in focus, that is, diarrhea, bloating, abdominal
pain, nausea, tiredness, constipation, heartburn and headache,
was significantly associated with PVA (Mahadev et al., 2017)
(Table 3).
Five studies (Kaukinen et al., 2007; Tuire et al., 2012; Pekki
et al., 2015, 2017; Haere et al., 2016) reported gastrointestinal
symptom scores measured with the Gastrointestinal Symptom
Rating Scale (GSRS) or its irritable bowel syndrome-adapted
version (GSRS-IBS). Four of which performed statistical analysis
and reported no association between histology and the scores
consistently (Kaukinen et al., 2007; Pekki et al., 2015, 2017;
Haere et al., 2016) (Table 4). Results were similar in quality of
life measured with the Psychological General Well-Being Index
(PGWB) and/or the 36-Item Short Form Health Survey (SF-36)
(Kaukinen et al., 2007; Tuire et al., 2012; Pekki et al., 2015, 2017)
(Table 4).
Metabolic Bone Disease and Bone Fractures
Four studies assessed bone mineral density in univariate analysis
(Valdimarsson et al., 1994; Walters et al., 1995; Kaukinen
et al., 2007; Pekki et al., 2015) (Table 5). Patients with PVA
tended to have lower forearm, femoral and trochanter Z-scores
(Valdimarsson et al., 1994); and lower femoral T-score with
similar femoral Z- and lumbar T- and Z-scores than those
with MR (Pekki et al., 2015). One study showed a reduced
bone mineral density with PVA (OR = 24.5, p < 0.0275
favoring MR) (Walters et al., 1995). Two studies investigated the
risk of osteoporosis in the long-term and reported conflicting
results: a case-control study reported an increased frequency of
osteoporosis with PVA (Kaukinen et al., 2007) but a cohort study
failed to confirm (Pekki et al., 2015).
Three studies (Valdimarsson et al., 1994; Lebwohl et al., 2014;
Pekki et al., 2017) reported no association between fractures and
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TABLE 3 | Presence of symptoms in celiac patients with persistent villous atrophy and mucosal recovery.
Study Symptoms assessed
prospectively?
Symptoms assessed
at the time of
follow-up biopsy?
Only strict
GFD?
Symptoms N0 of symptomatic
pts/total with
persistent villous
atrophy (% of total)
N0 of symptomatic
pts/total with
mucosal recovery
(% of total)
Statistics
(atrophy vs. recovery)
Timing of follow-up
biopsy
(from CeD diagnosis)
SYMPTOMATIC vs. ASYMPTOMATIC PTS
Carroccio
et al. (2008)
Yes Yes Yes Specifieda 36 cases/45 pts
(80)
6 cases/24 pts
(25)
OR = 12
(CI: 3.7–38.9)
(p < 0.0001, favors recovery);
adjusted OR = 3.2
(CI: 1.6–6.4)
(p = 0.001, favors recovery)b
6.5 y and 6.1 y (means for
groups) with 3.6 y and 4.6 y
(SDs for groups)
Fang et al.
(2017)
No Yes Yes Specifiedc 53 cases/77 pts
(69)
116 cases/203 pts
(57)
OR = 1.656
(CI: 0.949–2.889) (p = 0.076, favors
recovery)
2 y (min)
Kaukinen
et al. (2007)
Yes Nod Yes Not specified 4 cases/13 pts
(31)
Not reported Not reported 8 y and 10 y (medians for
groups) with 3–30 y (range)
Leonard et al.
(2017)
No Yes No Not specified 11 cases/20 pts
(55)
58 cases/83 pts
(70)
p = NS 2.4 y (median) with 1–12 y
(range) and 1.4–4 y (Q1-Q3)
Selby et al.
(1999)
(?) Noe Yes Not specified 5 cases/26 pts
(19)
3 cases/24 pts
(13)
Not reported Not reported
Thornquist
et al. (1993)
Yes Noe Yes Specifiedf 1 case/4 pts
(25)
7 cases/9 pts
(78)
Not reported 17 y (mean) with 15–18 y
(range?)
SPECIFIC SYMPTOMs (PRESENT vs. ABSENT)
Cammarota
et al. (2007)
Yes Yes No Diarrhea 10 cases/49 pts
(20)
2 cases/16 pts
(13)
Not reported 6–14m (range)
Bloating 9 cases/49 pts
(18)
3 cases/16 pts
(19)
Abdominal pain 5 cases/49 pts
(10)
7 cases/16 pts
(44)
Carroccio
et al. (2008)
Yes Yes Yes Typical symptoms 6 cases/45 pts
(13)
0 cases/24 pts
(0)
p = 0.005 (favors recovery) 6.5 y and 6.1 y (means for
groups) with 3.6 y and 4.6 y
(SDs for groups)
GERD-like symptoms 9 cases/45 pts
(20)
3 cases/24 (13) p = 0.01 (favors recovery)
lower abdominal
symptoms
21 cases/45 pts
(47)
3 cases/21 pts
(14)
p = 0.001 (favors recovery)
Ghazzawi
et al. (2014)
No Yes Yes Abdominal pain 2 cases/5 pts
(40)
17 cases/34 pts
(50)
Not reported 2 y (mean) with 22m (SD)
and 4–120m (range)
Diarrhea 2 cases/5 pts
(40)
5 cases/34 pts
(15)
Constipation 0 cases/5 pts
(0)
5 cases/34 pts
(15)
(Continued)
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TABLE 3 | Continued
Study Symptoms assessed
prospectively?
Symptoms assessed
at the time of
follow-up biopsy?
Only strict
GFD?
Symptoms N0 of symptomatic
pts/total with
persistent villous
atrophy (% of total)
N0 of symptomatic
pts/total with
mucosal recovery
(% of total)
Statistics
(atrophy vs. recovery)
Timing of follow-up
biopsy
(from CeD diagnosis)
Mahadev
et al. (2017)
No Yes Yes Bloating 431 cases/511 pts
(84)
736 cases/834 pts
(88)
p = 0.04 (favors atrophy), p = 0.001
(favors atrophy), p = 0.0009 (favors
atrophy), and p = 0.04 (favors
recovery) for bloating, abdominal
pain, nausea, and heartburn,
respectively; p = NS for the other
comparisons;
adjusted p = NS for all
comparisonsg
4 y (median) with 1 y (min)
Abdominal pain 410 cases/511 pts
(80)
724 cases/834 pts
(87)
Tiredness 421 cases/511 pts
(82)
708 cases/834
(85)
Diarrhea 375 cases/511 pts
(73)
643 cases/834pts
(77)
Nausea 239 cases/511 pts
(47)
451 cases/834 pts
(54)
Constipation 263 cases/511 pts
(51)
421 cases/834 pts
(50)
Heartburn 140 cases/511 pts
(27)
186 cases/834 pts
(22)
Headache 112 cases/511 pts
(22)
208 cases/834 pts
(25)
Multivariate analyses are highlighted with bold. aSymptoms included typical (chronic diarrhea, weight loss, anemia), GERD-like, and lower abdominal symptoms (abdominal pain, constipation). bAnalysis was adjusted for age, gender,
duration of GFD, diagnostic histological severity. cSymptoms included abdominal pain, bloating, nausea, fatigue, diarrhea, bloody stool, steatorrhea, and weight loss. dSymptoms were assessed 4–5 years after the follow-up biopsy.
eSymptoms were evaluated after follow-up biopsy (interval undetermined). fSymptoms included gastrointestinal and malabsorptive symptoms, such as diarrhea, borborygmi, abdominal pain, fatty stool, and anemia. gThe analysis was
adjusted for age, gender, body mass index, duration of GFD, medications, and laboratory tests. (?) indicates uncertainty. CeD, celiac disease; CI, confidence interval; GERD, gastroesophageal reflux disease; GFD, gluten-free diet;
m, month; min, minimum; OR, odds ratio; pts, patients; NS, non-significant; SD, standard deviations; Q1-Q3, 25 and 75% quartiles; y, year.
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TABLE 4 | Symptom scores and quality of life indices in celiac patients with persistent villous atrophy and mucosal recovery.
Study Symptoms
assessed
prospectively?
Symptoms assessed
at the time of
follow-up biopsy?
Only strict
GFD?
Tool Persistent villous atrophy Mucosal recovery Statistics
(atrophy vs.
recovery)
Timing of follow-up
biopsy (from CeD
diagnosis)N
0 of
pts
Score N0 of
pts
Score
GASTROINTESTINAL SYMPTOM SCORES
Pekki et al. (2017) Yes Noa No GSRS 200 Not reported 276 Not reported p = NS 1 y
Kaukinen et al.
(2007)
Yes Yes Yes GSRS 13 mean: 2.0 (CI:
1.4–2.6)
18 mean: 2.0 (CI:
1.7–2.3)
p = NS 8 y and 10 y (medians for
groups) with 3–30 y (range)
Pekki et al. (2015) Yes Yes No GSRS 85 Median: 1.5
(Q1-Q3: 1.3–1.8)
178 Median: 1.5
(Q1-Q3: 1.3-2.0)
p = 0.321 1 y
Noa No GSRS
∑
44b Median: 1.6
(Q1-Q3: 1.0–4.0)
∑
44b Median: 1.9
(Q1-Q3: 1.0–3.0)
p = 0.132 5 y (median)
Tuire et al. (2012) Yes Yes Yes GSRSc 7 Mean: 1.73 (CI:
1.39-2.07)
170 Not reported Not reported 2–41 y (range)
Haere et al. (2016) Yes Yes No GSRS-IBSd 7 Mean: 25.1 (SD
9.9)
116 Mean: 26.4 (SD:
9.9)
p = NS 9.3 y (mean) with 5 y (SD)
and 2 y (min)
QUALITY OF LIFE SCORES
Pekki et al. (2017) Yes Noa No PGWB 200 Not reported 276 Not reported p = NS 1 y
SF-36 p = NS
Kaukinen et al.
(2007)
Yes Yes Yes PGWB 13 Mean: 101 (CI:
94-108)
18 Mean: 101 (CI:
92-110)
p = NS 8 y and 10 y (medians for
groups) with 3–30 y (range)
Pekki et al. (2015) Yes Yes No PGWB 85 Median: 112
(Q1-Q3: 102–118)
178 Median: 111
(Q1-Q3: 100–117)
p = 0.699 1 y
Noa No PGWB
∑
44b median: 109
(Q1-Q3: 52–124)
∑
44b Median: 108
(Q1-Q3: 62–121)
p = 0.416 5 y (median)
Tuire et al. (2012) Yes Yes Yes PGWBb 7 Mean: 112.7 (CI:
110.6–114.8)
170 Not reported Not reported 2–41 y (range)
aScores were assessed years after the follow-up biopsy. bThe number of patients were not reported for atrophic and recovery groups separately. cSubdimensions of GSRS were reported within the original article in detail. dA 3-day
modified version of the original tool was used. CeD, celiac disease; CI, confidence interval; GFD, gluten-free diet; GSRS, Gastrointestinal Symptom Rating Scale; GSRS-IBS: Gastrointestinal Symptom Rating Scale for Irritable Bowel
Syndrome; min, minimum; NS, non-significant; PGWB, Psychological General Well-Being; pts, patients; SF-36, Short Form Health Survey-36; Q1-Q3, 25% and 75% quartiles; SD: standard deviation.
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TABLE 5 | Bone mineral density in celiac patients with persistent villous atrophy and mucosal recovery.
Study Parameter of
interest
assessed
prospectively?
Parameter of
interest
assessed at the
time of follow-up
biopsy?
Only strict
GFD?
Bone mineral density Persistent villous atrophy Mucosal recovery Statistics
(atrophy vs.
recovery)
Timing of follow-up
biopsy
(from CeD diagnosis)
Scores N0 of
pts
Scores N0 of
pts
T- AND Z-SCORES
Pekki et al. (2015) Yes Yes No Lumbar (T-score) Median: −1.1
(Q1-Q3: −2.2 to−0.2)
∑
152a Median: −0.7
(Q1-Q3: −1.7 to 0.4)
∑
152a p = 0.117 1 y
Femoral neck (T-score) Median: −1.1
(Q1-Q3: −1.9 to−0.5)
85 pts Median: −0.6
(Q1-Q3: −1.5 to 0.0)
178 pts p = 0.024
(favors recovery)
Lumbar (Z-score) Median: −0.5
(Q1-Q3: −1.3 to −0.1)
∑
159a Median: 0.1
(Q1-Q3: −1.1 to 0.9)
∑
159a p = 0.376
Femoral neck (Z-score) Median: −0.5
(Q1-Q3: −0.7 to −0.1)
∑
140a Median: −0.3
(Q1-Q3: −0.6 to 0.3)
∑
140a p = 0.323
Valdimarsson et al.
(1994)
Yes (?) No Forearm (Z-score) Not reported 13 pts Not reported 17 pts P < 0.01
(favors recovery)
8 y and 9 y (medians
for groups) with 4–14 y
(range)
Femoral neck (Z-score) p < 0.01
(favors recovery)
Femoral trochanter
(Z-score)
p < 0.05
(favors recovery)
Affected pts/total with
persistent villous atrophy (%
of total)
Affected pts/total with
mucosal recovery (% of total)
OSTEOPOROSIS AND OSTEOPENIA
Kaukinen et al.
(2007)
Yes Yes Yes Osteoporosis (T-score
≤−2.5 SD)
7 cases/12 pts
(58)
4 cases/18 pts
(22)
p = 0.04 8 y and 10 y (medians
for groups) with 3–30 y
(range)
Osteopenia (T-score
between −1.0 and
−2.4 SD)
4 cases/12 pts
(33)
8 cases/18 pts (44) p = NS
Pekki et al. (2015) Yes Nob No Osteoporosis (T- and
Z-scores)
8 cases/71 pts
(14)
16 cases/134 pts
(13)
p = 0.850 5 y (median)
Walters et al.
(1995)
Yes Nob Yes Osteopenia (Z-score) 7 cases/9 pts
(78)
1 case/8 pts
(13)
p < 0.0275
(favors recovery)
2 y (min)
All measurements were performed with dual-energy X-ray absorptiometry except in forearm bone mineral density in the study of Valdimarsson et al. (1994) which used single-photon absorptiometry. aThe number of patients were not
reported for atrophic and recovery groups separately. bParameter was assessed years after follow-up biopsy. (?) indicates uncertainty. GFD, gluten-free diet; m, month; min, minimum; NS, non-significant; pts, patients Q1-Q3, 25% and
75% quartiles; SD, standard deviation; y, year.
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TABLE 6 | Fractures in celiac patients with persistent villous atrophy and mucosal recovery.
Study Events
assessed
prospectively?
Only
strict
GFD?
Type of
fracture
Persistent
villous atrophy
Mucosal
recovery
Statistics
(atrophy vs.
recovery)
Timing of
follow-up biopsy
(from CeD
diagnosis)
Follow-up period
Valdimarsson
et al. (1994)
Yes No Any fracture 9 fractures in 6
cases/13 pts
5 fractures in 5
cases/17 pts
p = NS for the
number of patients
with fractures
8 y and 9 y
(medians for
groups) with 4–14
y (range)
Not reported
Pekki et al.
(2017)
Yes No Any fracture 53 cases/200 pts 80 cases/276 pts p = 0.859 1 y Years (?)
Lebwohl et al.
(2014)
No (?) Any fracturea 492 cases/34409
PYO
483 cases/36418
PYO
HR = 0.93
(CI: 0.82–1.06)b
6 m−5 y (range) 8.6 y (median) with
6.9–15.7 y (Q1-Q3)
from follow-up
biopsy
Likely
osteoporotic
fracturea
124 cases/20617
PYO
96 cases/11916
PYO
HR = 1.11
(CI: 0.84-1.46)b
Hip fracturea 26 cases/37925
PYO
63 cases/39851
PYO
HR = 1.67
(CI: 1.05–2.66)b
(favors recovery)
Multivariate analyses are highlighted with bold. aDetailed data are available in the original article. bThe analysis was adjusted for age, gender, duration of celiac disease, calendar period,
and educational attainment. (?) indicates uncertainty. CI, confidence interval; GFD, gluten-free diet; HR, hazard ratio (reference group: mucosal recovery); NS, non-significant; PYO,
person-years observation; Q1-Q3: 25 and 75% quartiles.
follow-up histology, except in the frequency of hip fractures being
seemingly increased after a 5-years follow-up with PVA (adjusted
HR= 2.18, CI: 1.17–4.05) (Lebwohl et al., 2014) (Table 6).
Micro- and Macronutrients
Table 7 summarizes the laboratory findings.
The association of water-soluble vitamins and follow-up
histology is understudied. We found the numerical values of
vitamins B2 and B6 levels or their laboratory indicators in patients
with MR and PVA but the studies did not perform statistical
comparison (Dickey et al., 2008). Regarding vitamins B12 and B9
(folic acid) levels, studies found no difference between groups by
histology (Pekki et al., 2015; Fang et al., 2017). No reports are
available on other water-soluble vitamins.
Reports on fat-soluble vitamins are scarce. Only numerical
data are available on vitamin A without statistical comparison
made by the authors (Valdimarsson et al., 1994). Patients with
PVA tended to have lower 25-hydroxyvitamin D level [and
total calcium (Fang et al., 2017)], though serum parathyroid
hormone (Valdimarsson et al., 1994; Pekki et al., 2015), ionized
calcium (Valdimarsson et al., 1994; Pekki et al., 2015) and
alkaline phosphatase (Valdimarsson et al., 1994) seemed similar
in patients with MR and PVA.
Zinc but not copper deficiency may be associated with PVA
(39 vs. 14% for zinc deficiency with PVA and MR, respectively,
p= 0.0005) (Fang et al., 2017).
Anemia
Nine studies reported on hemoglobin, four studies in
dichotomies (aaemic vs. non-anemic) and five as continuous
data (Thornquist et al., 1993; Kemppainen et al., 1998; Ciacci
et al., 2002; Cammarota et al., 2007; Kaukinen et al., 2007; Tuire
et al., 2012; Pekki et al., 2015; Fang et al., 2017; Mahadev et al.,
2017), of which four reported statistical comparisons (Kaukinen
et al., 2007; Pekki et al., 2015; Fang et al., 2017; Mahadev et al.,
2017) (Table 8). Hemoglobin levels proved to be not statistically
different in two studies (Kaukinen et al., 2007; Pekki et al., 2015).
Another two studies examined the frequency of anemia (Fang
et al., 2017; Mahadev et al., 2017), of which one found it more
frequent with PVA (22 vs. 18%, p = 0.04) (Mahadev et al., 2017).
However, the association was not confirmed after adjusting for
co-variates (p= 0.236).
Body Mass Index
Of the six studies reporting body mass index, three provided
statistical evidence on having no significant difference between
groups while the other three reported numerical values without
analysis (Valdimarsson et al., 1994; Kaukinen et al., 2007; Dickey
et al., 2008; Tuire et al., 2012; Pekki et al., 2015; Cornell et al.,
2016) (Table 9).
Malignant Tumors and Other Co-morbid Conditions
Four studies reported the overall rate of malignant tumors during
follow-up (Kaukinen et al., 2007; Tuire et al., 2012; Pekki et al.,
2015, 2017), two of which performed univariate analysis where
event rates were 4.5 vs. 5.1% (p = 0.762) and 11.3 vs. 6% (p =
0.116) with PVA vs. MR, respectively (Pekki et al., 2015, 2017)
(Table 10).
Incidence of lymphomas was 1.4 vs. 1.6% (p = 0.968) with
PVA vs.MR in univariate analysis (Pekki et al., 2015). In a registry
analysis, PVA had an adjusted HR of 2.26 (CI: 1.18–4.34) for the
overall rate of lymphomas, being true for the subgroup of non-
Hodgkin lymphomas but not for the subset of T-cell lymphomas
(Lebwohl et al., 2013b) (Table 10).
Sporadic records concerned other co-morbid conditions.
Cardiovascular diseases including heart failure and atrial
fibrillation (Lebwohl et al., 2015a), hypertension (Mahadev
et al., 2017), serious infections (including sepsis, streptococcal,
Frontiers in Physiology | www.frontiersin.org 11 November 2019 | Volume 10 | Article 1408
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TABLE 7 | Vitamins, minerals, and homocysteine in celiac patients with persistent villous atrophy and mucosal recovery.
Study Parameter of
interest
assessed
prospectively?
Parameter of
interest
assessed at the
time of follow-up
biopsy?
Only
strict
GFD?
Laboratory study Persistent villous atrophy Mucosal recovery Statistics
(atrophy vs.
recovery)
Timing of
follow-up
biopsy (from
CeD
diagnosis)
Total N0 of
pts
N0 of pts with
deficiency (% of
total)
Level Total N0 of
pts
N0 of pts with
deficiency (% of
total)
Level
VITAMIN B2 (RIBOFLAVIN)
Dickey et al.
(2008)
Yes Yes Yes EGRAC 24 Mean: 1.38
(SD: 0.19)
41 Mean: 1.28
(SD: 0.13)
Not reported 1 y (min)
VITAMIN B6 (PYRIDOXINE)
Dickey et al.
(2008)
Yes Yes Yes Plasma pyridoxal
phosphate (nmol/l,
vitamin)
24 Mean: 69.9
(SD: 24.0)
41 Mean: 91.0
(SD: 43.3)
Not reported 1 y (min)
VITAMIN B9 (FOLIC ACID)
Dickey et al.
(2008)
Yes Yes Yes Erythrocyte folic
acid (nmol/l)
24 Mean: 900
(SD: 574)
41 Mean: 1048
(SD: 791)
Not reported 1 y (min)
Dickey et al.
(2008)
Yes Yes Yes Serum folic acid
(nmol/l)
24 Mean: 23.5
(SD: 22.8)
41 Mean: 25.7
(SD: 31.5)
Not reported 1 y (min)
Kemppainen
et al. (1998)
No Yes (?) Erythrocyte folic
acid (cut-off: not
reported)
37 3 (8) 3 0 (0) Not reported 1 y
Pekki et al.
(2015)
Yes Yes No Erythrocyte folic
acid (nmol/l)
∑
142a Median: 548
(Q1-Q3:
424–676)
∑
142a Median: 508
(Q1-Q3:
383–650)
p = 0.547 1 y
Thornquist
et al. (1993)
Yes Nob No Serum folic acid 4 Not reportedd 9 Not reportedd Not reported 17 y (mean)
with 15–18 y
(range ?)
Tuire et al.
(2012)
Yes Yes Yes Erythrocyte folic
acid (nmol/l)
7 Median: 486
(range:
243–1,849)
170 Not reported Not reported 2–41 y (range)
VITAMIN B12 (COBALAMIN)
Dickey et al.
(2008)
Yes Yes Yes Serum vitamin B12
(pmol/l)
24 Mean: 242.5
(SD: 105.8)
41 Mean: 276.6
(SD: 137.1)
Not reported 1 y (min)
Fang et al.
(2017)
No Noc Yes Serum vitamin B12
(cut-off: 180 ng/l)
60 2 (3) 175 3 (2) p = 0.6023 2 y (min)
Kemppainen
et al. (1998)
No Yes (?) Serum vitamin B12
(cut-off: not
reported)
37 1 (3) 3 0 (0) Not reported 1 y
Pekki et al.
(2015)
Yes Yes No Serum vitamin B12
(pmol/l)
85 Median: 383
(Q1-Q3:
286–464)
178 Median: 341
(Q1-Q3:
269-428)
p = 0.153 1 y
Thornquist
et al. (1993)
Yes Nob No Serum vitamin B12 4 Not reported
d 9 Not reportedd Not reported 17 y (mean)
with 15–18 y
(range ?)
(Continued)
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TABLE 7 | Continued
Study Parameter of
interest
assessed
prospectively?
Parameter of
interest
assessed at the
time of follow-up
biopsy?
Only
strict
GFD?
Laboratory study Persistent villous atrophy Mucosal recovery Statistics
(atrophy vs.
recovery)
Timing of
follow-up
biopsy (from
CeD
diagnosis)
Total N0 of
pts
N0 of pts with
deficiency (% of
total)
Level Total N0 of
pts
N0 of pts with
deficiency (% of
total)
Level
VITAMIN A (RETINOL)
Kemppainen
et al. (1998)
No Yes (?) Serum vitamin A
(cut-off: not
reported)
37 5 (14) 3 0 (0) Not reported 1 y
VITAMIN D (CHOLECALCIFEROL)
Fang et al.
(2017)
No Noc Yes Serum total
25-hydroxy
vitamin D2 and D3
(cut-off: 25 ng/ml)
55 17 (31) 174 14 (8) p = 0.0001
(favors
recovery)
2 y (min)
Valdimarsson
et al. (1994)
Yes (?) No Serum 25-hydroxy
vitamin D
13 Median: 52
(range:
18–91)
17 Median: 80
(range: 37-95)
p < 0.05
(favors
recovery)
8 y and 9 y
(medians for
groups) with
4–14 y (range)
IRON AND FERRITIN
Fang et al.
(2017)
No Noc Yes Serum ferritin
(cut-off: males: 24
mcg/l, females: 11
mcg/l)
69 7 (10) 165 21 (13) p = 0.6636 2 y (min)
Kemppainen
et al. (1998)
No Yes (?) Serum total iron
(cut-off: not
reported)
37 15 (41) 3 0 (0) Not reported 1 y
Kemppainen
et al. (1998)
No Yes (?) Serum ferritin
(cut-off: not
reported)
37 5 (14) 3 0 (0) Not reported 1 y
Pekki et al.
(2015)
Yes Yes No Serum total iron
(µmol/l)
∑
144a Median: 19.6
(Q1-Q3:
13.4–24.4)
∑
144a Median: 17.6
(Q1-Q3:
14.0-21.5)
p = 0.245 1 y
Souroujon
et al. (1982)
Yes Yes (?) Serum ferritin 2 Mean: 16.2
(SD: 1.38)
34 Mean: 25.7
(SD: 1.82)
Not reported 1 y
CALCIUM
Fang et al.
(2017)
No Noc Yes Serum total
calcium (cut-off:
8.9 mg/dl)
65 13 (20) 164 4 (2) p < 0.0001
(favors
recovery)
2 y (min)
(Continued)
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TABLE 7 | Continued
Study Parameter of
interest
assessed
prospectively?
Parameter of
interest
assessed at the
time of follow-up
biopsy?
Only
strict
GFD?
Laboratory study Persistent villous atrophy Mucosal recovery Statistics
(atrophy vs.
recovery)
Timing of
follow-up
biopsy (from
CeD
diagnosis)
Total N0 of
pts
N0 of pts with
deficiency (% of
total)
Level Total N0 of
pts
N0 of pts with
deficiency (% of
total)
Level
Pekki et al.
(2015)
Yes Yes No Serum ionized
calcium (mmol/l)
∑
95a Median: 1.25
(Q1-Q3:
1.21-1.28)
∑
95a Median: 1.24
(Q1-Q3:
1.21-1.27)
p = 0.708 1 y
Valdimarsson
et al. (1994)
Yes (?) No Serum ionized
calcium (mmol/l)
13 Median: 1.24
(range:
1.16-1.31)
17 Median: 1.24
(range:
1.19-1.34)
p = NS 8 y and 9 y
(medians for
groups) with
4–14 y (range)
ZINC
Fang et al.
(2017)
No Noc Yes serum zinc
(cut-off: 0.66
mcg/ml)
46 18 (39) 145 20 (14) p = 0.0005
(favors
recovery)
2 y (min)
Kemppainen
et al. (1998)
No Yes (?) serum zinc
(cut-off: not
reported)
37 10 (27) 3 0 (0) Not reported 1 y
COPPER
Fang et al.
(2017)
No Noc Yes Serum copper
(0.75 mcg/ml)
51 0 (0) 149 4 (3) p = 0.5740 2 y (min)
HOMOCYSTEINE
Dickey et al.
(2008)
Yes Yes Yes Plasma
homocysteine
(µmol/l)
24 Mean: 11.4
(SD: 5.5)
41 Mean: 10.4
(SD: 2.6)
Not reported 1 y (min)
aOnly the total N0 of pts was given. bParameter was measured years after the follow-up biopsy. cParameter was measured within 1 month of follow-up biopsy. dValues were within the normal range for all patients and not reported for
recovery and atrophic groups separately. (?) indicates uncertainty. CeD, celiac disease; EGRAC, erythrocyte glutathione reductase activation coefficient; GFD, gluten-free diet; m, month; min, minimum; NS, non-significant; Q1-Q3, 25%
and 75% quartiles; SD, standard deviation; y, year.
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TABLE 8 | Anemia and hemoglobin levels in celiac patients with persistent villous atrophy and mucosal recovery.
Study Parameter of
interest
assessed
prospectively?
Parameter of
interest
assessed at the
time of follow-up
biopsy?
Only
strict
GFD?
Laboratory
study
Persistent villous atrophy Mucosal recovery Statistics
(atrophy vs.
recovery)
Timing of
follow-up biopsy
(from CeD
diagnosis)
Total N0 of
pts
N0 of pts with
deficiency (% of
total)
Level Total N0 of
pts
N0 of pts with
deficiency (% of
total)
Level
Cammarota
et al. (2007)
Yes Yes No Iron-
deficiency
anemia (Hb
cut-off: not
reported)
49 16 (33) 16 4 (25) Not reported 6–14m (range)
Ciacci et al.
(2002)
No Yes No Hb (g/l) 93 Mean: 133 297 Not reporteda Not reported 7.78 y (mean)
Fang et al.
(2017)
No Nob Yes anemia (Hb
cut-off:
males: 135
g/l, females:
120 g/l)
97 14 (14) 249 32 (13) p = 0.7255 2 y (min)
Kaukinen
et al. (2007)
Yes Yes Yes Hb (g/l) 13 mean: 121
(CI: 114–128)
18 Mean: 13.2
(CI:
12.6–13.8)
p = NS 8 y and 10 y
(medians for
groups) with 3–30
y (range)
Kemppainen
et al. (1998)
No Yes (?) anemia (Hb
cut-off: not
reported)
37 7 (19) 3 1 (33) Not reported 1 y
Mahadev
et al. (2017)
No Yes Yes anemia (Hb
cut-off: not
reported)
511 114 (22) 834 148 (18) unadjusted
p = 0.04,
adjusted
p = 0.236c
4 y (median) with 1
y (min)
Pekki et al.
(2015)
Yes Yes No Hb (g/l)
∑
153f Median: 145
(Q1-Q3:
134–150)
∑
153f Median: 147
(Q1-Q3:
147-151)
p = 0.342 1 y
Thornquist
et al. (1993)
Yes Nod No Hb 4 Not reportede 9 Not reportede Not reported 17 y (mean) with
15–18 y (range ?)
Tuire et al.
(2012)
Yes Yes Yes Hb (g/l) 7 Median: 140
(range:
128–161)
170 Not reporteda Not reported 2–41 y (range)
Multivariate analyses are highlighted with bold. aValues were given by Marsh 0 and 1–2 separately. bParameter was assessed within 1-month of follow-up biopsy. cThe analysis was adjusted for age, gender, body mass index, duration
of GFD, medications, laboratory tests, and symptoms. dParameter was measured years after the follow-up biopsy. eValues by recovery and atrophy were not reported separately. (?) indicates uncertainty. CeD, celiac disease; CI:
confidence interval; GFD, gluten-free diet; Hb, hemoglobin; m, month; min, minimum; NS, non-significant; Q1-Q3, 25% and 75% quartiles; SD, standard deviation; y, year.
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pneumococcal, influenza, herpes zoster, and Clostridium difficile
infections) (Emilsson et al., 2018) and adverse pregnancy
outcomes (Lebwohl et al., 2015b) were not influenced by
follow-up histology. However, there was a significant reduction
in the frequency of respiratory and dermatological diseases
(Pekki et al., 2017) and in the rate of elevated aspartate and
alanine transaminase levels with MR (Mahadev et al., 2017). In
contrast, MR predisposed to developing anxiety and depression
(Ludvigsson et al., 2018) as well as epilepsy (Kurien et al.,
2018). The effect of follow-up histology on immune-mediated
co-morbidities including dermatitis herpetiformis is severely
understudied (Valdimarsson et al., 1994; Tuire et al., 2012;
Mahadev et al., 2017).
All-Cause and Cause-Specific Mortality
Four studies reported all-cause mortality during follow-up
(Kaukinen et al., 2007; Rubio-Tapia et al., 2010; Lebwohl et al.,
2013a; Pekki et al., 2015), two of which adjusted the analysis for
significant co-variates (Rubio-Tapia et al., 2010; Lebwohl et al.,
2013a). In this regard, MR seemed to be protective in a small
retrospective study with a HR of 0.13 (CI: 0.02–1.06) (Rubio-
Tapia et al., 2010), not confirmed by a nationwide registry analysis
(HR = 1.0, CI: 0.86–1.19 for PVA) (Lebwohl et al., 2013a). In
the latter study, results were consistent on cardiovascular, tumor-
related and respiratory deaths: the beneficial effect of MR was not
confirmed (Lebwohl et al., 2013a) (Table 11).
DISCUSSION
Summary of Findings
Whether the follow-up biopsy in asymptomatic CeD is needed
is uncertain, and, to date, no systematic review has addressed this
question. AchievingMR is a desirable goal of treatment; however,
findings of reports which investigated its beneficial effects on
disease course are inconsistent. In line with our previous findings,
MR rates ranged from 9 to 97% across the studies included
(Szakacs et al., 2017). The fact that a considerable fraction of
CeD patients does not achieve MR underlines the importance of
investigating the potential prognostic role of follow-up histology.
One important conclusion of this review is that many
asymptomatic patients do not achieve MR, and vice versa, many
symptomatic patients do achieve MR. Analogously, MR cannot
guarantee the symptoms to disappear, whereas PVA is often
associated with persisting symptoms, even on a long-term follow-
up exceeding 1 year (Tables 2, 3). Persisting symptoms may
indicate poor dietary adherence (Abdulkarim et al., 2002; Leffler
et al., 2007; Haere et al., 2016) or gluten-independent food
intolerance (Carroccio et al., 2008) but other diseases, such as
pancreatic insufficiency or small intestinal bacterial overgrowth,
might be in the background (Fine et al., 1997). Noteworthy
that a few studies included patients with questionable adherence
to gluten-free diet, although a top-quality study established a
straight relationship between persisting symptoms and PVA in
co-variate-adjusted analysis of patients with good adherence
(Carroccio et al., 2008). Studies used various definitions for
assessing symptoms; some did not report how symptoms
were specified at all. Although a smaller study favored MR
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TABLE 10 | Malignant tumors in celiac patients with persistent villous atrophy and mucosal recovery.
Study Only
strict
GFD?
Malignant
tumors
N0 of cases/Total
(%)
Statistics Timing of follow-up
biopsy
(from diagnosis of
CeD)
Follow-up period
Persistent
villous atrophy
Mucosal
recovery
Kaukinen et al.
(2007)
Yes Any malignant
tumora
3 cases/13 pts
(23.1)
0 cases/18 pts
(0.0)
Not reported 8 y and 10 y (medians
for groups) (range:
3–30 y)
4–5 years from
follow-up biopsy
Lebwohl et al.
(2013b)
No Any lymphoma 41 cases/4317 pts
(0.9)
12 cases/3308 pts
(0.4)
HR = 2.26
(CI: 2.28–4.34)d
1.3 (median) (range: 6
m−5 y)
10.6 y (median)
from diagnosis of
CeD and 8.9 y
(median) from
follow-up biopsy
Any non-Hodgkin
lymphoma
34 cases/4317 pts
(0.8)
8 cases/3308 pts
(0.2)
HR = 2.82
(CI: 1.29–6.17)d
Any B-cell
lymphoma
4 cases/4317 pts
(<0.1)
3 cases/3308 pts
(<0.1)
HR = 0.97
(CI: 0.21–4.49)d
Any T-cell
lymphoma
10 cases/4317 pts
(0.2)
2 cases/3308 pts
(<0.1)
HR = 3.51
(CI: 0.75–16.34)d
Pekki et al. (2015) No Any malignant
tumor
9 cases/200 pts
(4.5)
14 cases/276 pts
(5.1)
p = 0.762 1 y 8 y (median) from
diagnosis of CeD
Pekki et al. (2017) No Any malignant
tumorb
8 cases/71 pts
(11.3)
8 cases/134 pts
(6.0)
p = 0.116 1 y 5 y (median) from
diagnosis of CeD
Any lymphoma 1 case/71 pts
(1.4)
2 cases/134 pts
(1.5)
p = 0.968
Tuire et al. (2012) Yes Any malignant
tumorc
0 cases/7 pts
(0.0)
4 cases/170 pts
(2.4)
Not reported 7 y, 9 y, and 10 y
(medians for groups)
(range: 2-41 y)
From diagnosis of
CeD until
follow-up biopsy
Multivariate analyses are highlighted with bold. aCases included T-cell lymphoma, small bowel adenocarcinoma, and carcinoid tumor; bCases included the uterus, breast, lung, pancreas,
urinary bladder, and prostate tumors; lymphomas, and sarcomas. cCases included breast, uterine, and prostate cancer; and lymphoma. dThe analysis was adjusted for age, sex, year
of follow-up biopsy, education, and duration of celiac disease at the time of follow-up biopsy. CeD, celiac disease; CI, confidence interval; GFD, gluten-free diet; HR, hazard ratio; pts,
patients; m, month; y, year.
regarding a set of individual symptoms (Carroccio et al.,
2008), the most extensive study including only symptomatic
patients found significant associations in univariate analysis
(with an unexpected inverse association between PVA and
heartburn). Interestingly, all associations proved to be non-
significant after adjusting for co-variates (Mahadev et al., 2017).
Self-reporting of subjective complaints may contribute to the
discrepant results. Use of symptom scales (Svedlund et al.,
1988) provided a comparable measure with homogenous results:
none of the studies attributed higher scores for those patients
with PVA compared to those with MR (Table 4). The same
association applies to quality of life; however, based on small
sets of patients (Table 4). Altogether, the diagnostic accuracy of
persisting symptoms seems insufficient for indicating a follow-up
biopsy. Evidence coming from the two prospective studies is not
enough to decide whether PVA precisely predicts the long-term
persistence of symptoms (Pekki et al., 2015, 2017) (Table 4).
PVA appears to be associated with radiologically detected
metabolic bone disease in univariate analysis (Table 5), which
translates into an increased risk of hip fractures (as an
independent predictor) but not into that of the overall fractures
(Table 6). Calcium malabsorption (Fang et al., 2017) together
with vitamin D deficiency (Valdimarsson et al., 1994; Fang et al.,
2017) are likely to be causative factors. Length of follow-up (not
standardized among studies) may be insufficient for restoring
bone mineral density (Pekki et al., 2015), especially in those
with severe bone impairment at diagnosis. Body mass index, as
an important co-variate, seems to be independent of mucosal
status (Table 9).
Laboratory studies describing vitamin and mineral levels tend
to recover on an adequate diet. Patients on a long-term strict
gluten-free diet may suffer from vitamin deficiencies (Hallert
et al., 2002, 2009), this phenomenon might be explained by the
vitamin- and micronutrient-poor nature of the gluten-free diet
as compared to a balanced gluten-containing diet (Thompson,
1999). None of the studies adjusted for dietary adherence and
vitamin supplementation which might counteract malabsorption
and masked the effects of PVA. Variability in clinical and
histological severity at diagnosis might delay villous restitution,
thereby affecting vitamin status (not taken into account in the
studies) (Kemppainen et al., 1998). Besides, improvement of
histology might lag behind the recovery of laboratory values
(Pekki et al., 2015), although the length of follow-up exceeded
1 year in all studies (Table 7).
Regarding mortality, the adjusted HRs calculated in the
individual studies attributed a neutral effect to MR and PVA
(Table 11) (Rubio-Tapia et al., 2010; Lebwohl et al., 2013a).
Findings were similar on malignant tumors, except in certain
lymphoproliferative diseases based on an extensive registry
analysis (noteworthy that data were not adjusted for dietary
adherence) (Lebwohl et al., 2013b). A possible explanation could
be that the increment in rates of mortality and tumors with PVA
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TABLE 11 | Studies reporting on mortality in celiac patients with persistent villous atrophy and mucosal recovery.
Study Only
strict
GFD?
Mortality N0 of cases/Total
(%)
Statistics
(atrophy vs.
recovery)
Timing of follow-up
biopsy
(from diagnosis of
CeD)
Follow-up period
Persistent
villous atrophy
Mucosal
recovery
Kaukinen et al.
(2007)
Yes All-cause 2 cases/13 pts
(15.4)
1 case/18 pts
(5.6)
Not reported 8 y and 10 y (medians
for groups) (range:
3–30 y)
4–5 years from follow-up
biopsy
Pekki et al. (2015) No All-cause 10 cases/71 pts
(14.1)
12 cases/134 pts
(9.0)
p = 0.259 1 y 8 y (median) from diagnosis
of CeD
Rubio-Tapia et al.
(2010)
No All-cause 10 cases/117 pts
(8.5)
1 case/124 pts
(0.8)
HR = 0.13
(CI: 0.02–1.06)a
p = 0.06
(favors
recovery)
Min: 5m 10 y from diagnosis of CeD
Lebwohl et al.
(2013a)
No All-cause
Cardiovascular
Malignancy
Respiratory
Unknown number
of 3,317 ptsb
Unknown number
of 4,331 ptsb
HR = 1.37 (CI:
1.16–1.62)c
(favors recovery);
HR = 1.01
(CI: 0.86–1.19)
after
adjustmentd
1.3 (median) (range: 6
m−5 y)
11.5 y (median) from
diagnosis of CeD and 9.9 y
(median) from follow-up
biopsy
HR = 1.03
(CI: 0.76-1.38)d
HR = 1.20
(CI: 0.88-1.66)d
HR = 0.78
(CI: 0.41-1.48)d
Multivariate analyses are highlighted with bold. aThe analysis was adjusted for age and gender. bTotal mortality of the cohort of patients was 8.0%. cThe analysis was unadjusted. dThe
analysis was adjusted for age, gender, calendar period of diagnosis, education level, and length of follow-up. CeD, celiac disease; CI, confidence interval; GFD, gluten-free diet; HR,
hazard ratio; pts, patients; m, month; y, year.
was counteracted by a decreased risk of ovarian, endometrial
and breast cancer, likely due to lower body weight and/or earlier
menopause (Ludvigsson et al., 2012; Lebwohl et al., 2013a).
Strengths and Limitations
Our study has several strengths. The question we raised is
unique without known previous systematic review. We carried
out an extensive systematic search with high coverage of patient-
important outcomes in a transparent manner by independent
(and pre-trained) investigators with good inter-rater agreement.
The quality of the included papers was rigorously assessed.
Although the amount of data presented in the tables would
be enough for meta-analytical aggregations that we intended to
do initially (as declared in the protocol of the work, see the
PROSPERO record); finally, our team decided not to do so
because of several concerns. The decision-making algorithm is
presented in Figure 2.
We are aware that the evidence suffers from several
limitations. (1) Most studies did not recruit patients immediately
after the diagnosis of CeD (29/31, 94%), did not take the follow-
up biopsy after recruitment (23/31, 74%) and did not assess
the disease course prospectively. (2) Although the diagnosis
of CeD was mainly biopsy-proven, only two papers included
newly diagnosed cases and observed them longitudinally until
the follow-up biopsy. (3) Details of histological sampling and
processing (e.g., sampling site, number of tissue samples,
orientation, staining) were not consistently reported across
papers, while the procedures often deviated from recent
gold standards (e.g., samples were taken from the jejunum,
histological classification systems were not specified). Similarly,
the definition of villous atrophy varied across the studies. (4)
Observational studies are vulnerable to bias: in registry analyses,
data of the deceased were often missing (survivorship bias),
attendance to regular control visits was incomplete (attrition
bias), baseline differences between groups of patients with MR
and those with PVA were rarely balanced with co-variate-
adjusted analyses (selection bias), study samples were not taken
consistently from the general CeD population with consecutive
recruitment (selection bias), and investigators assessing the
outcomes were rarely blind to mucosal status (performance bias,
detection bias). (5) Most evidence came from studies focusing on
adults while an inverse association between age and rate of MR
is well-known (Szakacs et al., 2017). (6) A strict gluten-free diet
was not a criterion in several studies, the length of diet varied. (7)
Publication bias cannot be reliably assessed in systematic reviews.
CONCLUSION
Implications for Practice
The results of publications on the prognostic role of follow-up
histology (that is, MR and PVA) are not in agreement. Some
adverse outcomes (e.g., persistent symptoms and metabolic bone
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FIGURE 2 | Decision-making algorithm. Based on several arguments, we decided not to perform a meta-analysis.
disease)may bemore commonwith PVA; however, achievingMR
alone cannot guarantee a favorable clinical course to our current
knowledge. The question as to whether taking a follow-up biopsy
is beneficial has remained a matter of debate.
Implications for Research
With a view to the future, prospective cohort studies are urged to
be organized to collect decisive evidence on the prognostic role
of follow-up histology.
DATA AVAILABILITY STATEMENT
All datasets analyzed this study are included in the
manuscript/supplementary files.
AUTHOR CONTRIBUTIONS
ZS and JB conceptualized the study. AM, DD, VB, LS,
AV, and RH collected the data. NG performed the formal
analysis and designed the figures. ZS assessed the quality of
studies. ZG, DC, and MS interpreted the results. ÁV, ZS,
JB, and BE drafted the manuscript. ÁV and PH supervised
the work. All authors approved the final draft submitted,
involved in the study design, edited, read and approved the
final manuscript.
FUNDING
This study was supported by an Economic Development and
Innovation Operative Programme Grant (GINOP 2.3.2-15-
2016-00048), an Institutional Development for Enhancing
Intelligent Specialization Grant (EFOP-3.6.2-16-2017-0006)
of the National Research, Development and Innovation
Office, the ÚNKP-18-3-I and ÚNKP-19-3-I New National
Excellence Program of the Ministry of Human Capacities.
Sponsors had no effect on study design, data collection,
analysis, interpretation of the findings, or preparation of
the manuscript.
REFERENCES
Abdulkarim, A. S., Burgart, L. J., See, J., and Murray, J. A. (2002). Etiology of non-
responsive celiac disease: results of a systematic approach. Am. J. Gastroenterol.
97, 2016–2021. doi: 10.1111/j.1572-0241.2002.05917.x
Bai, J. C., Fried, M., Corazza, G. R., Schuppan, D., Farthing, M., Catassi, C., et al.
(2013).World gastroenterology organisation global guidelines on celiac disease.
J. Clin. Gastroenterol. 47, 121–126. doi: 10.1097/MCG.0b013e31827a6f83
Bardella, M. T., Velio, P., Cesana, B. M., Prampolini, L., Casella, G.,
Di Bella, C., et al. (2007). Coeliac disease: a histological follow-up
study. Histopathology 50, 465–471. doi: 10.1111/j.1365-2559.2007.02
621.x
Biagi, F., Vattiato, C., Agazzi, S., Balduzzi, D., Schiepatti, A., Gobbi, P.,
et al. (2014). A second duodenal biopsy is necessary in the follow-up of
adult coeliac patients. Ann. Med. 46, 430–433. doi: 10.3109/07853890.2014.9
13378
Frontiers in Physiology | www.frontiersin.org 19 November 2019 | Volume 10 | Article 1408
Szakács et al. Follow-Up Histology in Celiac Disease
Cammarota, G., Cuoco, L., Cesaro, P., Santoro, L., Cazzato, A., Montalto, M.,
et al. (2007). A highly accurate method for monitoring histological recovery in
patients with celiac disease on a gluten-free diet using an endoscopic approach
that avoids the need for biopsy: a double-center study. Endoscopy 39, 46–51.
doi: 10.1055/s-2006-945044
Carroccio, A., Ambrosiano, G., Di Prima, L., Pirrone, G., Iacono, G., Florena, A.
M., et al. (2008). Clinical symptoms in celiac patients on a gluten-free diet.
Scand. J. Gastroenterol. 43, 1315–1321. doi: 10.1080/00365520802200044
Catassi, C., Gatti, S., and Fasano, A. (2014). The new epidemiology of
celiac disease. J. Pediatr. Gastroenterol. Nutr. 59 (Suppl. 1), S7–9.
doi: 10.1097/01.mpg.0000450393.23156.59
Ciacci, C., Cirillo, M., Cavallaro, R., and Mazzacca, G. (2002). Long-term follow-
up of celiac adults on gluten-free diet: prevalence and correlates of intestinal
damage. Digestion 66, 178–185. doi: 10.1159/000066757
Corazza, G. R., and Villanacci, V. (2005). Coeliac disease. J. Clin. Pathol. 58,
573–574. doi: 10.1136/jcp.2004.023978
Cornell, H. J., Czyzewska, A., Macrae, F. A., Rydzewska, G., Nasierowska-
Gutmejer, A., Bednarczuk, A., et al. (2016). The effect of enzyme
supplementation on symptoms and duodenal histology in celiac patients. Int.
J. Cell. Dis. 4, 40–47. doi: 10.12691/ijcd-4-2-2
Di Sabatino, A., and Corazza, G. R. (2009). Coeliac disease. Lancet 373, 1480–1493.
doi: 10.1016/S0140-6736(09)60254-3
Dickey, W., Ward, M., Whittle, C. R., Kelly, M. T., Pentieva, K., Horigan, G., et al.
(2008). Homocysteine and related B-vitamin status in coeliac disease: effects of
gluten exclusion and histological recovery. Scand. J. Gastroenterol. 43, 682–688.
doi: 10.1080/00365520701881118
Emilsson, L., Lebwohl, B., Green, P. H., Murray, J. A., Marild, K., and
Ludvigsson, J. F. (2018). Mucosal healing and the risk of serious infections
in patients with celiac disease. United European Gastroenterol. J. 6, 55–62.
doi: 10.1177/2050640617707868
Fang, H., King, K. S., Larson, J. J., Snyder, M. R., Wu, T. T., Gandhi, M. J., et al.
(2017). Undetectable negative tissue transglutaminase IgA antibodies predict
mucosal healing in treated coeliac disease patients. Aliment. Pharmacol. Ther.
46, 681–687. doi: 10.1111/apt.14250
Fine, K. D., Meyer, R. L., and Lee, E. L. (1997). The prevalence and causes
of chronic diarrhea in patients with celiac sprue treated with a gluten-
free diet. Gastroenterology 112, 1830–1838. doi: 10.1053/gast.1997.v112.pm91
78673
Ghazzawi, Y., Rubio-Tapia, A., Murray, J. A., and Absah, I. (2014). Mucosal
healing in children with treated celiac disease. J. Pediatr. Gastroenterol. Nutr.
59, 229–231. doi: 10.1097/MPG.0000000000000390
Haere, P., Hoie, O., Schulz, T., Schonhardt, I., Raki, M., and Lundin, K.
E. (2016). Long-term mucosal recovery and healing in celiac disease is
the rule - not the exception. Scand. J. Gastroenterol. 51, 1439–1446.
doi: 10.1080/00365521.2016.1218540
Haines, M. L., Anderson, R. P., and Gibson, P. R. (2008). Systematic review:
the evidence base for long-term management of coeliac disease. Aliment.
Pharmacol. Ther. 28, 1042–1066. doi: 10.1111/j.1365-2036.2008.03820.x
Hallert, C., Grant, C., Grehn, S., Granno, C., Hulten, S., Midhagen, G.,
et al. (2002). Evidence of poor vitamin status in coeliac patients on a
gluten-free diet for 10 years. Aliment. Pharmacol. Ther. 16, 1333–1339.
doi: 10.1046/j.1365-2036.2002.01283.x
Hallert, C., Svensson, M., Tholstrup, J., and Hultberg, B. (2009). Clinical
trial: B vitamins improve health in patients with coeliac disease
living on a gluten-free diet. Aliment. Pharmacol. Ther. 29, 811–816.
doi: 10.1111/j.1365-2036.2009.03945.x
Hayden, J. A., Cote, P., and Bombardier, C. (2006). Evaluation of the quality
of prognosis studies in systematic reviews. Ann. Intern. Med. 144, 427–437.
doi: 10.7326/0003-4819-144-6-200603210-00010
Kaukinen, K., Peraaho, M., Lindfors, K., Partanen, J., Woolley, N., Pikkarainen,
P., et al. (2007). Persistent small bowel mucosal villous atrophy without
symptoms in coeliac disease. Aliment. Pharmacol. Ther. 25, 1237–1245.
doi: 10.1111/j.1365-2036.2007.03311.x
Kemppainen, T. A., Kosma, V. M., Janatuinen, E. K., Julkunen, R. J., Pikkarainen,
P. H., and Uusitupa, M. I. (1998). Nutritional status of newly diagnosed
celiac disease patients before and after the institution of a celiac disease diet–
association with the grade of mucosal villous atrophy. Am. J. Clin. Nutr. 67,
482–487. doi: 10.1093/ajcn/67.3.482
Koskinen, O., Collin, P., Lindfors, K., Laurila, K., Maki, M., and Kaukinen,
K. (2010). Usefulness of small-bowel mucosal transglutaminase-2 specific
autoantibody deposits in the diagnosis and follow-up of celiac disease. J. Clin.
Gastroenterol. 44, 483–488. doi: 10.1097/MCG.0b013e3181b64557
Kurien, M., Ludvigsson, J. F., Sanders, D. S., Zylberberg, H. M., Green, P.
H., Sundelin, H. E. K., et al. (2018). Persistent mucosal damage and risk
of epilepsy in people with celiac disease. Eur. J. Neurol. 25, 592–e538.
doi: 10.1111/ene.13564
Lebwohl, B., Emilsson, L., Frobert, O., Einstein, A. J., Green, P. H., and Ludvigsson,
J. F. (2015a). Mucosal healing and the risk of ischemic heart disease or atrial
fibrillation in patients with celiac disease; a population-based study. PLoS ONE
10:e0117529. doi: 10.1371/journal.pone.0117529
Lebwohl, B., Granath, F., Ekbom, A., Montgomery, S. M., Murray, J. A., Rubio-
Tapia, A., et al. (2013a). Mucosal healing and mortality in coeliac disease.
Aliment. Pharmacol. Ther. 37, 332–339. doi: 10.1111/apt.12164
Lebwohl, B., Granath, F., Ekbom, A., Smedby, K. E., Murray, J. A., Neugut, A. I.,
et al. (2013b). Mucosal healing and risk for lymphoproliferative malignancy
in celiac disease: a population-based cohort study. Ann. Intern. Med. 159,
169–175. doi: 10.7326/0003-4819-159-3-201308060-00006
Lebwohl, B., Michaelsson, K., Green, P. H., and Ludvigsson, J. F. (2014). Persistent
mucosal damage and risk of fracture in celiac disease. J. Clin. Endocrinol. Metab.
99, 609–616. doi: 10.1210/jc.2013-3164
Lebwohl, B., Stephansson, O., Green, P. H., and Ludvigsson, J. F. (2015b). Mucosal
healing in patients with celiac disease and outcomes of pregnancy: a nationwide
population-based study. Clin. Gastroenterol. Hepatol. 13, 1111–1117.e1112.
doi: 10.1016/j.cgh.2014.11.018
Leffler, D. A., Dennis, M., Hyett, B., Kelly, E., Schuppan, D., and Kelly, C.
P. (2007). Etiologies and predictors of diagnosis in non-responsive celiac
disease. Clin. Gastroenterol. Hepatol. 5, 445–450. doi: 10.1016/j.cgh.2006.
12.006
Leonard, M.M.,Weir, D. C., Degroote, M., Mitchell, P. D., Singh, P., Silvester, J. A.,
et al. (2017). Value of IgA tTG in predicting mucosal recovery in children with
celiac disease on a gluten-free diet. J. Pediatr. Gastroenterol. Nutr. 64, 286–291.
doi: 10.1097/MPG.0000000000001460
Ludvigsson, J. F., Bai, J. C., Biagi, F., Card, T. R., Ciacci, C., Ciclitira,
P. J., et al. (2014). Diagnosis and management of adult coeliac disease:
guidelines from the British Society of Gastroenterology. Gut 63, 1210–1228.
doi: 10.1136/gutjnl-2013-306578
Ludvigsson, J. F., Lebwohl, B., Chen, Q., Broms, G., Wolf, R. L., Green, P.
H. R., et al. (2018). Anxiety after coeliac disease diagnosis predicts mucosal
healing: a population-based study. Aliment. Pharmacol. Ther. 48, 1091–1098.
doi: 10.1111/apt.14991
Ludvigsson, J. F., West, J., Ekbom, A., and Stephansson, O. (2012). Reduced risk
of breast, endometrial and ovarian cancer in women with celiac disease. Int. J.
Cancer 131, E244–250. doi: 10.1002/ijc.26454
Mahadev, S., Murray, J. A., Wu, T. T., Chandan, V. S., Torbenson, M. S., Kelly, C.
P., et al. (2017). Factors associated with villus atrophy in symptomatic coeliac
disease patients on a gluten-free diet. Aliment. Pharmacol. Ther. 45, 1084–1093.
doi: 10.1111/apt.13988
Marsh, M. N. (1992). Gluten, major histocompatibility complex, and the small
intestine. A molecular and immunobiologic approach to the spectrum
of gluten sensitivity (’celiac sprue’). Gastroenterology 102, 330–354.
doi: 10.1016/0016-5085(92)91819-P
Moher, D., Liberati, A., Tetzlaff, J., and Altman, D. G. (2009). Preferred reporting
items for systematic reviews and meta-analyses: the PRISMA statement. BMJ
339:b2535. doi: 10.1136/bmj.b2535
Oberhuber, G., Granditsch, G., and Vogelsang, H. (1999). The
histopathology of coeliac disease: time for a standardized report
scheme for pathologists. Eur. J. Gastroenterol. Hepatol. 11, 1185–1194.
doi: 10.1097/00042737-199910000-00019
Pekki, H., Kurppa, K., Maki, M., Huhtala, H., Laurila, K., Ilus, T., et al. (2017).
Performing routine follow-up biopsy 1 year after diagnosis does not affect long-
term outcomes in coeliac disease. Aliment. Pharmacol. Ther. 45, 1459–1468.
doi: 10.1111/apt.14048
Pekki, H., Kurppa, K., Maki, M., Huhtala, H., Sievanen, H., Laurila, K., et al.
(2015). Predictors and significance of incomplete mucosal recovery in celiac
disease after 1 year on a gluten-free diet. Am. J. Gastroenterol. 110, 1078–1085.
doi: 10.1038/ajg.2015.155
Frontiers in Physiology | www.frontiersin.org 20 November 2019 | Volume 10 | Article 1408
Szakács et al. Follow-Up Histology in Celiac Disease
Reilly, N. R., Husby, S., Sanders, D. S., and Green, P. H. R. (2017). Coeliac
disease: to biopsy or not? Nat. Rev. Gastroenterol. Hepatol. 15:60–66.
doi: 10.1038/nrgastro.2017.121
Rubio-Tapia, A., Hill, I. D., Kelly, C. P., Calderwood, A. H., and Murray,
J. A. (2013). ACG clinical guidelines: diagnosis and management of
celiac disease. Am. J. Gastroenterol. 108, 656–676. doi: 10.1038/ajg.
2013.79
Rubio-Tapia, A., Rahim, M. W., See, J. A., Lahr, B. D., Wu, T. T., and Murray,
J. A. (2010). Mucosal recovery and mortality in adults with celiac disease
after treatment with a gluten-free diet. Am. J. Gastroenterol. 105, 1412–1420.
doi: 10.1038/ajg.2010.10
Selby, W. S., Painter, D., Collins, A., Faulkner-Hogg, K. B., and Loblay, R. H.
(1999). Persistent mucosal abnormalities in coeliac disease are not related to
the ingestion of trace amounts of gluten. Scand. J. Gastroenterol. 34, 909–914.
doi: 10.1080/003655299750025390
Souroujon, M., Ashkenazi, A., Lupo, M., Levin, S., and Hegesh, E. (1982).
Serum ferritin levels in celiac disease. Am. J. Clin. Pathol. 77, 82–86.
doi: 10.1093/ajcp/77.1.82
Svedlund, J., Sjodin, I., and Dotevall, G. (1988). GSRS–a clinical rating scale
for gastrointestinal symptoms in patients with irritable bowel syndrome
and peptic ulcer disease. Dig. Dis. Sci. 33, 129–134. doi: 10.1007/BF015
35722
Szakacs, Z., Matrai, P., Hegyi, P., Szabo, I., Vincze, A., Balasko, M., et al.
(2017). Younger age at diagnosis predisposes to mucosal recovery in celiac
disease on a gluten-free diet: a meta-analysis. PLoS ONE 12:e0187526.
doi: 10.1371/journal.pone.0187526
Thompson, T. (1999). Thiamin, riboflavin, and niacin contents of the gluten-
free diet: is there cause for concern? J. Am. Diet. Assoc. 99, 858–862.
doi: 10.1016/S0002-8223(99)00205-9
Thornquist, H., Jacobsen, G. S., Dahl, L. B., and Marhaug, G. (1993).
Coeliac disease and gluten-free diet: a following-up study of fifteen
young adults. Ann. Nutr. Metab. 37, 295–301. doi: 10.1159/0001
77780
Tuire, I., Marja-Leena, L., Teea, S., Katri, H., Jukka, P., Paivi, S., et al. (2012).
Persistent duodenal intraepithelial lymphocytosis despite a long-term strict
gluten-free diet in celiac disease. Am. J. Gastroenterol. 107, 1563–1569.
doi: 10.1038/ajg.2012.220
Valdimarsson, T., Toss, G., Ross, I., Lofman, O., and Strom,
M. (1994). Bone mineral density in coeliac disease. Scand.
J. Gastroenterol. 29, 457–461. doi: 10.3109/003655294090
96838
Walters, J. R., Banks, L. M., Butcher, G. P., and Fowler, C. R. (1995). Detection of
low bone mineral density by dual energy x ray absorptiometry in unsuspected
suboptimally treated coeliac disease. Gut 37, 220–224. doi: 10.1136/gut.
37.2.220
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2019 Szakács, Gede, Gyöngyi, Solymár, Csupor, Ero˝ss, Vincze, Mikó,
Vasas, Szapáry, Dobszai, Balikó, Hágendorn, Hegyi and Bajor. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Physiology | www.frontiersin.org 21 November 2019 | Volume 10 | Article 1408
